Ownership and insider activity for Barinthus Biotherapeutics plc (BRNS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease.
Price
| Price | $0.74 |
| Market Cap | $30M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-09 | Oxford Science Enterprises plc | U-Tender | 8,797,770 | $977K |
| 2026-09-09 | Wright Robin | D-Return | 18,604 | $79K |
| 2026-09-09 | Wright Robin | D-Return | 19,197 | $44K |
| 2026-09-09 | Wright Robin | D-Return | 19,516 | $46K |
| 2026-09-09 | Wright Robin | D-Return | 20,174 | $20K |
| 2026-09-09 | Wright Robin | D-Return | 48,256 | $5 |
| 2026-09-09 | Wright Robin | D-Return | 20,394 | $2 |
| 2026-09-09 | Wright Robin | D-Return | 34,328 | $584K |
| 2026-09-09 | Scheeren Joseph | D-Return | 23,000 | $2 |
| 2026-09-09 | Scheeren Joseph | D-Return | 34,328 | $584K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.4M | $43.3M | $214.1M | $194.4M | $142.1M | $110.7M | $70.5M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $3.9M | $518000 | $11.7M | $18.0M | $7.9M | $7.1M | $1.3M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $16.2M | $47.9M | $226.8M | $213.0M | $156.9M | $125.7M | $77.8M |
| Property, Plant & Equipment | $2.8M | $2.8M | $9.1M | $15.7M | $19.4M | $11.8M | $5.2M |
| Goodwill | 0 | 0 | $12.6M | $12.2M | $12.2M | 0 | 0 |
| Intangible Assets | 0 | 0 | $31.4M | $28.3M | $25.1M | $21.9M | $14.3M |
| Total Assets | $19.0M | $50.7M | $280.7M | $270.2M | $214.5M | $160.3M | $98.2M |
| Accounts Payable | $3.9M | $4.7M | $2.4M | $3.7M | $1.6M | $2.5M | $350000 |
| Short-term Debt | 0 | 0 | $159000 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $5.8M | $7.6M | $11.2M | $12.2M | $12.6M | $15.7M | $10.0M |
| Long-term Debt | 0 | $44.7M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $41.1M | $53.8M | $28.2M | $27.0M | $27.5M | $30.2M | $23.9M |
| Retained Earnings | -$37.9M | -$57.7M | -$108.6M | -$103.2M | -$176.6M | -$237.7M | -$304.1M |
| Total Equity | -$22.4M | -$3.5M | $252.1M | $242.9M | $186.8M | $130.0M | $74.2M |
| Total Debt | $1.8M | $46.4M | $7.2M | $8.8M | $13.0M | $12.0M | $11.3M |
| Net Debt | -$9.7M | $3.1M | -$206.8M | -$185.6M | -$129.1M | -$98.7M | -$59.2M |
| Working Capital | $10.5M | $40.3M | $215.6M | $200.8M | $144.3M | $110.1M | $67.8M |
Financial Health
| Debt / Equity | 0.18 |
| Current Ratio | 5.54 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -4.62 |
Profitability
| Return on Equity | -59.18% |
| Return on Invested Capital | -61.15% |
| Return on Assets | -50.97% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALGS · CVM · INMB · KPTI · KZR · MDCX · MRSN
Explore sector: Healthcare · Biotechnology
More sections of BRNS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks